Anti-CD3 x Anti-TFRC Bispecific Antibody (IgG-IgG) (BSIG-104)

Anti-CD3 x Anti-TFRC Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD3 and anti-TFRC parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Erythroleukemia; Lymphoma therapy.

Datasheet INQUIRY

Specifications

Targets

CD3 & TFRC

Type

IgG-IgG

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Erythroleukemia; Lymphoma

Targets

Target 1

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Target 2

TFRC

Gene ID

7037

UniProt ID

P02786

Alternative Names

TFRC; transferrin receptor; T9; TR; TFR; p90; CD71; TFR1; TRFR; transferrin receptor protein 1; transferrin receptor (p90, CD71)

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD3 x Anti-TFRC Bispecific Antibody (IgG-IgG) (BSIG-104). Click the button below to contact us or submit your feedback about this product.

Anti-CD3 x Anti-TFRC Bispecific Antibody (IgG-IgG) (CAT#: BSIG-104)

Specifications

Targets

Customer Reviews and Q&As